Inhibitex to Present at Three Upcoming Conferences
May 28 2010 - 9:28AM
Business Wire
Inhibitex, Inc. (NASDAQ:INHX), a biopharmaceutical company
focused on developing products to treat and prevent serious
infectious diseases, announced that Russell H. Plumb, President and
Chief Executive Officer, is scheduled to present an overview of the
company and its pipeline of differentiated antiviral compounds at
the following three conferences:
-- Noble Financial 6th Annual Equity Conference on Monday, June
7, 2010 at 10:00 am EDT. The conference is being held at The
Seminole Hard Rock Hotel in Hollywood, Florida. The presentation
will be simultaneously webcast and can be accessed by visiting the
Investors section of the Inhibitex website
at www.inhibitex.com. Shortly following the live webcast a
replay will also be available on the Company website.
-- Jefferies Global Life Sciences Conference on Friday, June 11,
2010 at 10:30 am EDT. The conference is being held at The Grand
Hyatt Hotel in New York City, New York.
-- ThinkEquity Mid-Year Checkup on Healthcare on Wednesday, June
16, 2010 at 8:30 am EDT. The conference is being held at The
Princeton Club in New York City, New York.
About Inhibitex
Inhibitex, Inc., headquartered in Alpharetta, Georgia, is a
biopharmaceutical company focused on developing products to treat
serious infectious diseases. The Company’s pipeline includes
FV-100, which is in Phase II clinical development, for the
treatment of shingles, INX-189, a nucleotide polymerase inhibitor
for the treatment of chronic hepatitis C infections currently in a
Phase I study, and a staphylococcal vaccine based on its
proprietary MSCRAMM protein platform that is partnered with Pfizer
and currently in a Phase I study.
For additional information about the Company, please visit
www.inhibitex.com.
Inhibitex® and MSCRAMM® are registered trademarks of Inhibitex,
Inc.
Inhibitex, Inc. (MM) (NASDAQ:INHX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Inhibitex, Inc. (MM) (NASDAQ:INHX)
Historical Stock Chart
From Jul 2023 to Jul 2024